ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Nuclear transcription factor (NF-κB) >IκB / IKK inhibitors >TPCA-1

TPCA-1

TPCA-1 Suppliers list
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +undefined-21-51877795
Email: ivan@atkchemical.com
Products Intro: Product Name:TPCA-1
CAS:507475-17-4
Purity:98% Package:10MG;50MG;100MG,1G,5G,10G.100G
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: +8618523575427
Email: sales@conier.com
Products Intro: Product Name:tpca-1
CAS:507475-17-4
Purity:0.99 Package:1kg
Company Name: career henan chemical co
Tel: +86-0371-86658258 +8613203830695
Email: factory@coreychem.com
Products Intro: Product Name:TPCA-1
CAS:507475-17-4
Purity:99% Package:100g;1USD
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Products Intro: Product Name:TPCA-1
CAS:507475-17-4
Purity:99.29% Package:2mg;38USD|5mg;61USD|10mg;97USD Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: Dideu Industries Group Limited
Tel: +86-29-89586680 +86-15129568250
Email: 1026@dideu.com
Products Intro: Product Name:TPCA-1
CAS:507475-17-4
Purity:99.9% Package:25kgs/Drum;200kgs/Drum Remarks:FDA GMP CEP Approved Manufacturer

TPCA-1 manufacturers

  • TPCA-1
  • TPCA-1 pictures
  • $38.00
  • 2026-06-05
  • CAS:507475-17-4
  • Purity: 99.29%
  • Supply Ability: 10g
  • TPCA-1
  • TPCA-1 pictures
  • $1.00
  • 2019-12-23
  • CAS:507475-17-4
  • Min. Order: 100g
  • Purity: 99%
TPCA-1 Basic information
Background
Product Name:TPCA-1
Synonyms:TPCA-1;2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide;5-(4-Fluorophenyl)-2-ureidothiophene-3-carboxamide;TPCA-1(TPCA 1);3-ThiophenecarboxaMide, 2-[(aMinocarbonyl)aMino]-5-(4-fluorophenyl)-;5-(4-Fluorophenyl)-2-ureidothiophene-3-carboxamide TPCA-1;TPCA-1 IKK-2 Inhibitor IV;GW683965
CAS:507475-17-4
MF:C12H10FN3O2S
MW:279.29
EINECS:
Product Categories:NF-kB
Mol File:507475-17-4.mol
TPCA-1 Structure
TPCA-1 Chemical Properties
Melting point >217°C (dec.)
Boiling point 442.6±45.0 °C(Predicted)
density 1.490
storage temp. 2-8°C
solubility DMSO: soluble5mg/mL, clear
pka13.12±0.50(Predicted)
form powder
color white to light brown
Stability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChI1S/C12H10FN3O2S/c13-7-3-1-6(2-4-7)9-5-8(10(14)17)11(19-9)16-12(15)18/h1-5H,(H2,14,17)(H3,15,16,18)
InChIKeySAYGKHKXGCPTLX-UHFFFAOYSA-N
SMILESNC(=O)Nc1sc(cc1C(N)=O)-c2ccc(F)cc2
Safety Information
Hazard Codes Xn
Risk Statements 22-36
Safety Statements 26
WGK Germany 3
Storage Class11 - Combustible Solids
MSDS Information
TPCA-1 Usage And Synthesis
DescriptionTPCA-1 (507475-17-4) selective inhibitor of IκB kinase 2 (IKK2) (IC50 = 17.9 nM).1 Inhibits production of pro-inflammatory cytokines in arthritis and other animal models of inflammation.1,2 Also attenuates NLRP3 inflammasome activation in THP-1 myeloid cells, and suppresses IL1β-induced proliferation, migration, and invasion of HeLa cells.3,4 Continuous exposure to TPCA-1 promotes expansion of hematopoietic stem/progenitor cells (HSPCs) via improved glycolysis and limited ROS production.5
UsesTPCA-1 is a direct dual inhibitor for both IKKβ (IKK-2) and STAT3. It inhibits STAT3 phosphorylation, DNA binding, and transactivation in vivo. Synergistic treatment of TPCA-1 with tyrosine kinase inhibitors (TKIs) can potentially be a more effective method for treating cancers.
DefinitionChEBI: 2-(carbamoylamino)-5-(4-fluorophenyl)-3-thiophenecarboxamide is a member of thiophenes and an aromatic amide.
Biological ActivityPotent, selective inhibitor of I κ B kinase-2 (IKK-2) (IC 50 = 17.9 nM) that displays > 22-fold selectivity over IKK-1 and > 550-fold selectivity over other kinases and enzymes. Inhibits production of pro-inflammatory cytokines in vitro and in vivo and inhibits NF- κ B nuclear localisation. Reduces the severity and onset of collagen-induced arthritis; anti-inflammatory.
Biochem/physiol ActionsTPCA-1 is a potent and selective inhibitor of human IκB kinase-2 (IKK-2) with IC50 = 17.9 nM for IKK-2 compared to 400nm for IKK-1. It has been used to study inhibition of IKK-2 to prevent inflammatory mediator release in animal models of arthritis and airway inflammation.
in vitrodetermination of the activity of tpca-1 against ten selected kinases, cox-1 and cox-2, showed the compound to be ~550-fold selective for ikk-2 versus ten of these enzymes. tpca-1 inhibits lipopolysaccharide-induced human monocyte production of tnf-α, il-6, and il-8 with an ic50 of 170 to 320 nm [1].
in vivoprophylactic administration of tpca-1 at 3, 10, or 20 mg/kg resulted in a dose dependent reduction in the severity of murine collagen-induced arthritis. the significantly reduced disease severity and delay of disease onset resulting from administration of tpca-1 at 10 mg/kg were comparable to the effects of the antirheumatic drug, etanercept [1].
storageStore at -20°C
BackgroundTPCA-1 blocks NF-κB signaling and suppresses the transcription of several pro-inflammatory cytokines through inhibition of the IκB kinase subunit IKKβ. Studies show that TPCA-1 specifically inhibits IKKβ and reduces inflammation and antigen-induced T cell proliferation in murine collagen-induced arthritis. TPCA-1 prevents recruitment of the transcription factor STAT3 to upstream kinases through interaction with the SH2 domain of STAT3. This limits the ability of cytokines and tyrosine kinases to induce STAT3 activity, which inhibits the ability of STAT3 to regulate cell growth and apoptosis. Treatment of non-small cell lung cancer cells with TPCA-1 represses cell proliferation, suggesting that TPCA-1 may be effective in treating some forms of cancer. Studies have examined the ability of TPCA-1 to mediate the inflammatory response through control of IKKβ and STAT3 signaling in animal models of arthritis, chronic periodontitis, and nasal epithelial inflammation.
References[1] PATRICIA L PODOLIN. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.[J]. Journal of Pharmacology and Experimental Therapeutics, 2005, 312 1: 373-381. DOI:10.1124/jpet.104.074484
[2] BO WANG. TPCA-1 negatively regulates inflammation mediated by NF-κB pathway in mouse chronic periodontitis model.[J]. Molecular Oral Microbiology, 2021: 192-201. DOI:10.1111/omi.12335
[3] ADELINE UNTERREINER . Pharmacological inhibition of IKKβ dampens NLRP3 inflammasome activation after priming in the human myeloid cell line THP-1[J]. Biochemical and biophysical research communications, 2021, 545: Pages 177-182. DOI:10.1016/j.bbrc.2021.01.051
[4] LIMIN TAO. IL-1β promotes cervical cancer through activating NF-κB/CCL-2.[J]. International journal of clinical and experimental pathology, 2021, 14 4: 426-433.
[5] QIHAO SUN. Continuous NF-κB pathway inhibition promotes expansion of human phenotypical hematopoietic stem/progenitor cells through metabolism regulation[J]. Experimental cell research, 2021, 399 2: Article 112468. DOI:10.1016/j.yexcr.2020.112468
TPCA-1 Preparation Products And Raw materials
Tag:TPCA-1(507475-17-4) Related Product Information
BAY 11-7082 Volasertib (BI 6727) BI 2536 Imiquimod Ibrutinib Aniline 4'-Hydroxyacetophenone 2-FLUOROPHENYL CYCLOPENTYL KETONE TRIS(PENTAFLUOROPHENYL)BORANE IKK 16 Selumetinib MG-132 Trametinib IKK Inhibitor III, BMS-345541 TPCA-1